Myeloproliferative neoplasm medical therapy: Difference between revisions
Shyam Patel (talk | contribs) No edit summary |
Shyam Patel (talk | contribs) |
||
Line 45: | Line 45: | ||
Weight gain, zoster, non-melanoma skin cancers, cytopenias | Weight gain, zoster, non-melanoma skin cancers, cytopenias | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | |||
Phlebotomy | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
Mechnically removes red blood cells from circulation | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*Induction: 450cc blood removal daily until hematocrit < 45% | |||
*Maintenance: One session every 2 months, with goal hematocrit < 45% | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
Iron deficiency anemia, fatigue, vasovagal episodes, pain at phlebotomy site | |||
|} | |} | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} |
Revision as of 18:22, 10 June 2018
Myeloproliferative Neoplasm Microchapters |
Differentiating myeloproliferative neoplasm from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Myeloproliferative neoplasm medical therapy On the Web |
American Roentgen Ray Society Images of Myeloproliferative neoplasm medical therapy |
Directions to Hospitals Treating Myeloproliferative neoplasm |
Risk calculators and risk factors for Myeloproliferative neoplasm medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]
Overview
The mainstay of therapy for myeloproliferative neoplasm is chemotherapy, aspirin, and palliative care. Treatment is directed at reducing the excessive numbers of blood cells.[1]
Medical Therapy
Medical therapy for myeloproliferative neoplasm is based on the specific subtype of myeloproliferative neoplasm.
Polycythemia vera
Therapy | Mechanism of Action | Dosing | Adverse Effects |
---|---|---|---|
Aspirin |
Irreversibly inhibits cyclooxygenase-1 and -2 (COX-1 and COX-2) |
81mg PO daily |
Mucosal bleeding Gastrointestinal bleeding |
Hydroxyurea |
Inhibits ribonucleotide reductase |
20mg/kg PO daily |
Anemia, thrombocytopenia, ulcerations, secondary cancers |
Ruxolitinib |
Inhibits JAK2 (tyrosine kinase inhibitor) |
10mg PO twice daily |
Weight gain, zoster, non-melanoma skin cancers, cytopenias |
Phlebotomy |
Mechnically removes red blood cells from circulation |
|
Iron deficiency anemia, fatigue, vasovagal episodes, pain at phlebotomy site |
References
- ↑ National Cancer Institute. Physician Data Query Database 2015.http://www.cancer.gov/types/leukemia/hp/cml-treatment-pdq#section/_19